newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

EIKN
  • Eikon Therapeutics announced full-text abstracts for four clinical candidates to be presented at the 2026 ESMO Congress in Madrid, Spain, beginning October 23, 2026.
  • Updates include data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001 (a TLR7/8 dual-agonist) combined with pembrolizumab & chemotherapy in stage 4 NSCLC.
  • The company will share updated cohort data from a Phase 1/2 study of EIK1003, a non-brain penetrant PARP1 inhibitor, as monotherapy & with chemotherapy in advanced solid tumors.
  • Initial data will be presented on EIK1003 in combination with abiraterone for metastatic prostate cancer.
  • Results from a Phase 1/2 study of EIK1004, a CNS-penetrant PARP1 inhibitor, in advanced solid malignancies will be discussed.
  • Preliminary safety, tolerability, & pharmacokinetic data for EIK1005, a WRN helicase inhibitor, will be provided.
  • CEO Roger M. Perlmutter highlighted seven abstracts covering new findings & progress across Eikon's oncology pipeline.
  • EIK1001 presentations include results from the squamous cohort & updated pooled results for TeLuRide-005, plus details on the upcoming TeLuRide-008 Phase 2/3 study.
  • EIK1003 and EIK1004 updates are scheduled for October 23, 2026, alongside EIK1005 data sessions on the same date.
  • EIK1005 will be presented as a novel Werner Helicase Inhibitor in monotherapy & combination with pembrolizumab for MSI-H or dMMR tumors.
  • Eikon is a late-stage clinical biopharmaceutical company focused on developing innovative oncology medicines using its proprietary single molecule tracking technology.